Jaime J. Kulisevsky
#160,159
Most Influential Person Now
Jaime J. Kulisevsky's AcademicInfluence.com Rankings
Jaime J. Kulisevskymedical Degrees
Medical
#3209
World Rank
#3666
Historical Rank
Neurology
#297
World Rank
#379
Historical Rank
Download Badge
Medical
Why Is Jaime J. Kulisevsky Influential?
(Suggest an Edit or Addition)Jaime J. Kulisevsky's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines (2012) (1851)
- Rivastigmine for dementia associated with Parkinson's disease. (2004) (1113)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. (2005) (1030)
- Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies (2019) (871)
- MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI (2011) (700)
- Mild cognitive impairment in Parkinson disease (2010) (443)
- Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease (2010) (400)
- EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
- Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment (2015) (325)
- Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. (2003) (310)
- Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease (2008) (281)
- Mania following deep brain stimulation for Parkinson's disease. (2002) (259)
- Cognitive impairment and dementia in Parkinson's disease (2012) (255)
- Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families (2009) (249)
- Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging (2003) (224)
- Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia (2008) (189)
- Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment (2009) (180)
- A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. (1999) (177)
- Role of Dopamine in Learning and Memory (2000) (174)
- Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients (2000) (158)
- Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase (2016) (153)
- Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. (1996) (152)
- Controlled study of decision‐making and cognitive impairment in Parkinson's disease (2007) (145)
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
- Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations (1992) (143)
- Long‐term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease (2009) (142)
- Transcranial magnetic stimulation for treating depression. (2001) (139)
- Obsessive-compulsive disorder associated with brain lesions (1996) (128)
- Cognitive impairment in nondemented Parkinson's disease (2011) (128)
- Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. (2011) (127)
- Cut‐off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease (2008) (126)
- Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course (2012) (124)
- Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease (2013) (119)
- Motion of the cerebellar tonsils in Chiari type I malformation studied by cine phase-contrast MRI (1995) (118)
- Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review (2013) (118)
- Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. (2016) (116)
- Pergolide monotherapy in the treatment of early PD (1999) (104)
- Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease (2003) (103)
- Semantic Knowledge of Famous People in Mild Cognitive Impairment and Progression to Alzheimer’s Disease (2004) (98)
- Transcranial magnetic stimulation of the cerebellum in essential tremor: a controlled study. (2002) (98)
- Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. (1996) (89)
- Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study (2009) (83)
- Obsessivecompulsive disorder and traumatic brain injury: behavioral, cognitive, and neuroimaging findings. (2001) (83)
- Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease (2010) (79)
- The reliability of a deep learning model in clinical out-of-distribution MRI data: a multicohort study (2019) (78)
- SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study (2001) (76)
- Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. (2014) (75)
- Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy. (2000) (75)
- Changes in artistic style and behaviour in Parkinson’s disease: dopamine and creativity (2009) (74)
- Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. (2015) (71)
- Usefulness of P300 in Subjective Memory Complaints: A Prospective Study (2005) (71)
- N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease (2017) (70)
- Acute effects of immediate and controlled‐release levodopa on mood in Parkinson's disease: A double‐blind study (2007) (68)
- Frontal lobe activation during word generation studied by functional MRI (1996) (67)
- Bilateral pallidal stimulation for cervical dystonia: dissociated pain and motor improvement. (2000) (67)
- Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. (2013) (67)
- Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease (2010) (65)
- Effects of repetitive transcranial magnetic stimulation on memory subtypes: a controlled study (2003) (64)
- Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease (2010) (64)
- Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study (2014) (64)
- Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. (2019) (62)
- COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression (2016) (62)
- Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study) (2017) (60)
- Meige syndrome: Neuropathology of a case (1988) (59)
- Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing (2014) (58)
- Parkinson's disease‐cognitive rating scale: Psychometrics for mild cognitive impairment (2013) (57)
- Predicting dementia development in Parkinson's disease using Bayesian network classifiers (2013) (57)
- Regional Overlap of Pathologies in Lewy Body Disorders (2017) (55)
- The tools of the trade: A state of the art “How to Assess Cognition” in the patient with Parkinson's disease (2014) (53)
- MRI pallidal hyperintensity and brain atrophy in cirrhotic patients (1993) (52)
- [Movement disorders and AIDS]. (1996) (50)
- Routine Neurophysiologic Tremor Analysis as a Diagnostic Tool for Essential Tremor: A Prospective Study (2004) (48)
- Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death (2018) (47)
- Facial Emotion Recognition Impairment in Patients with Parkinson's Disease and Isolated Apathy (2010) (47)
- Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening (2008) (47)
- Meige syndrome: primary and secondary forms. (1988) (47)
- Apathy in Parkinson's Disease: More Than Just Executive Dysfunction (2013) (44)
- Bipolar Disorder in Adult Patients with Tourette’s Syndrome: A Clinical Study (1998) (44)
- Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. (1996) (43)
- Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders (2001) (43)
- Motor changes during sertraline treatment in depressed patients with Parkinson’s disease * (2008) (42)
- Hallucinations and sleep disturbances in Parkinson’s disease (2004) (41)
- New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. (2013) (41)
- A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia (2008) (40)
- Levodopa and executive performance in Parkinson's disease: A randomized study (2008) (40)
- Structural and metabolic brain correlates of apathy in Huntington's disease (2018) (40)
- Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain (2018) (39)
- [Advanced Parkinson's disease: clinical characteristics and treatment (part 1)]. (2013) (39)
- Non-demented Parkinson’s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes (2017) (39)
- [Weight gain after functional surgery for Parkinsons disease]. (2002) (39)
- PDD‐Short Screen: A brief cognitive test for screening dementia in Parkinson's disease (2010) (39)
- A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease (2002) (37)
- Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III (2016) (37)
- Hemiballismus and secondary mania following a right thalamic infarction (1993) (37)
- Unilateral parkinsonism and stereotyped movements following a right lenticular infarction (1996) (36)
- Update in therapeutic strategies for Parkinson's disease (2018) (36)
- Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease (2018) (35)
- Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. (2008) (35)
- Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro‐oculography in progressive supranuclear palsy: A prospective study (2003) (34)
- Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”? (2011) (34)
- Individual triptan selection in migraine attack therapy. (2009) (34)
- MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. (2015) (34)
- Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease (2020) (33)
- A Six‐month Study of Pergolide and Levodopa in De Novo Parkinson's Disease Patients (1998) (33)
- Review: Diagnosis and management of essential tremor and dystonic tremor (2009) (33)
- Validation of the Spanish version of Addenbrooke's Cognitive Examination III for diagnosing dementia. (2015) (33)
- Adenosine A2A-Receptor Antagonism and Pathophysiology of Parkinson’s Disease and Drug-Induced Movement Disorders (2011) (32)
- Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders (2010) (32)
- Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. (2015) (32)
- Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. (2020) (31)
- Advanced Parkinson's disease: Clinical characteristics and treatment. Part II (2013) (31)
- Expedited Publication (1996) (30)
- COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation (2019) (30)
- Telling true from false: cannabis users show increased susceptibility to false memories (2015) (29)
- Mild cognitive impairment in Parkinson’s disease (2019) (29)
- Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson’s Disease (2012) (28)
- Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study (2015) (28)
- A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment (2019) (27)
- Striatal hypometabolism in premanifest and manifest Huntington’s disease patients (2016) (27)
- Abnormalities of the acoustic startle reflex and reaction time in Gilles de la Tourette syndrome (2000) (26)
- Beneficial Effect of Donepezil on Sensorimotor Function After Stroke (2003) (26)
- Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances (2009) (26)
- Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction (1995) (25)
- Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
- The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population‐Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight (2019) (24)
- Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. (2017) (24)
- Parkinson's Disease: From Genetics to Clinical Practice (2013) (24)
- Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. (2019) (23)
- Motor and mental dysfunction in mother–daughter transmitted FXTAS (2010) (23)
- Brain Apparent Water Diffusion Coefficient Magnetic Resonance Image During a Prolonged Visual Aura (2010) (23)
- Botulinum toxin injection therapy for hemifacial spasm. (1988) (23)
- Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease (2021) (22)
- White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease (2019) (22)
- Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease (2019) (22)
- Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification (2018) (22)
- A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (2020) (21)
- Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network (2021) (21)
- The impact of bilingualism on brain structure and function in Huntington's disease. (2019) (21)
- Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease (2010) (21)
- Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease (2019) (21)
- Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson’s Disease: A Prospective, Cross-Sectional Study in Non-demented Patients (2015) (21)
- Identification of sixteen novel candidate genes for late onset Parkinson’s disease (2021) (21)
- Circadian Rhythm, Cognition, and Mood Disorders in Huntington's Disease. (2018) (20)
- Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity (2018) (20)
- Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. (1999) (20)
- Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial (2014) (19)
- Persistence of MRI hyperintensity of the globus pallidus in cirrhotic patients (1995) (19)
- Reactivation of posttraumatic stress disorder after minor head injury (1998) (19)
- Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial (2006) (19)
- Apathy in Parkinson's Disease. (2017) (18)
- Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. (2014) (18)
- The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies (2020) (18)
- Effects of internal globus pallidus stimulation on motor cortex excitability. (2002) (17)
- Magnetic resonance imaging pallidal hypersignal in cirrhotic subjects. (1996) (17)
- Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients (2016) (17)
- Advanced Parkinson's disease: clinical characteristics and treatment. Part II. (2013) (17)
- Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation (2019) (16)
- Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease (2020) (16)
- An active cognitive lifestyle as a potential neuroprotective factor in Huntington's disease (2019) (16)
- Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? (2017) (16)
- The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight (2019) (15)
- Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. (2007) (15)
- Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire (2018) (15)
- Tiagabine for essential tremor: An open‐label trial (2008) (15)
- Pergolide: Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease (2005) (14)
- Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease (2019) (14)
- Emerging Role of Safinamide in Parkinson's Disease Therapy (2015) (14)
- Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information (2020) (14)
- Validation of the Spanish version of Addenbrooke's Cognitive Examination III for diagnosing dementia (2015) (13)
- Motor Circuitry Re-organization After Pallidotomy in Parkinson Disease: A Neurophysiological Study of the Bereitschaftspotential, Contingent Negative Variation, and N30 (2002) (13)
- Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis (2021) (13)
- The Glass scale: a simple tool to determine severity in essential tremor. (2010) (13)
- LRP10 in α-synucleinopathies (2018) (13)
- Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson’s disease patients and its association with cognitive decline (2019) (13)
- Fluoxetine - induced mania in a patient with post-stroke depression (1993) (13)
- Unilateral blepharospasm stemming from a thalamomesencephalic lesion (1993) (12)
- Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease (2019) (12)
- Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? (2017) (12)
- Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases (2016) (12)
- Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson’s Disease (2020) (12)
- Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline (2018) (11)
- The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype (2020) (11)
- High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients (2019) (11)
- Suicide and attempted suicide in Tourette's syndrome: a case series with literature review. (2010) (11)
- Neurocardiovascular pathology in pre‐manifest and early‐stage Huntington's disease (2018) (11)
- CLU rs11136000 Promotes Early Cognitive Decline in Parkinson's Disease (2020) (11)
- Heroin and malignant coprolalia in Tourette's syndrome. (2003) (11)
- Predictors of clinically significant quality of life impairment in Parkinson’s disease (2021) (11)
- Structural brain correlates of dementia in Huntington’s disease (2020) (11)
- Efficacy of trazodone in antipsychotic-induced akathisia resistant to conventional treatment. (2012) (11)
- Levodopa does not aggravate postural tremor in Parkinson's disease. (1995) (11)
- Structural abnormalities in the substantia nigra and neighbouring nuclei in Tourette’s syndrome (2010) (11)
- Echopraxia and self-injurious behavior in Tourette's syndrome (1996) (10)
- Impaired face-like object recognition in premanifest Huntington's disease (2019) (10)
- Structural brain correlates of irritability and aggression in early manifest Huntington’s disease (2020) (10)
- Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration (2022) (10)
- [Psychogenic tremor: clinical, electrophysiologic and psychopathologic assessment]. (1997) (10)
- Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease (2020) (10)
- Trial of Deferiprone in Parkinson's Disease. (2022) (10)
- Unrecognized Tourette syndrome in adult patients referred for psychogenic tremor. (1998) (10)
- Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats (2009) (9)
- Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters (2019) (9)
- Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes (2021) (9)
- Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). (2017) (9)
- Treatment of Parkinson's disease in Spain (2003) (9)
- Comorbid Asperger and Tourette syndromes with localized mesencephalic, infrathalamic, thalamic, and striatal damage (2003) (9)
- An MDS Evidence‐Based Review on Treatments for Huntington's Disease (2021) (9)
- Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease (2022) (9)
- Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington’s disease (2019) (8)
- In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. (2021) (8)
- [Safinamide from daily clinical practice: first clinical steps]. (2017) (8)
- Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up (2021) (8)
- Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life (2021) (8)
- Parkinson's Disease—Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment (2016) (8)
- Impulse control disorders and dopaminergic treatments in Parkinson's disease. (2011) (8)
- Longitudinal evolution of prefrontal leucotomy in Tourett's syndrome (1995) (8)
- Preclinical Memory Profile in Alzheimer Patients with and without Allele APOE-epsilon4 (2004) (7)
- Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease. (2021) (7)
- Lack of prefrontal repetitive transcranial magnetic stimulation effects in time production processing (2005) (7)
- Historical crossroads in the conceptual delineation of apathy in Parkinson’s disease (2018) (7)
- Gerstmann‐Sträussler‐Scheinker Disease Presenting with Atypical Parkinsonism, but Typical Magnetic Resonance Imaging Findings of Prion Disease (2016) (6)
- Extrastriatal SPECT-DAT uptake correlates with clinical and biological features of de novo Parkinson's disease (2020) (6)
- Transcranial Magnetic Stimulation of the Cerebellum in Essential Tremor (2002) (6)
- Predictors of Loss of Functional Independence in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group (2021) (6)
- A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice (2020) (6)
- Short-lasting episodes of prosopagnosia in Parkinson's disease. (2013) (6)
- Abnormalities of the Bereitschaftspotential and MRI pallidal signal in non-encephalopathic cirrhotic patients. (1995) (6)
- Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinson’s Disease Is Modified by the SNCA rs356181 Polymorphism (2018) (6)
- Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
- Lacosamide, another therapeutic failure in essential tremor: An open‐label trial (2011) (5)
- “String Hallucinations”: Multimodal Tactile and Visual Hallucinations in Parkinson's Disease (2016) (5)
- Measuring impulsivity in Parkinson’s disease: a correlational and structural neuroimaging study using different tests (2020) (5)
- Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease (2021) (5)
- Reduced striato‐cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients (2018) (5)
- Preservation of brain metabolism in recently diagnosed Parkinson’s impulse control disorders (2020) (5)
- Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease (2021) (5)
- Perceptual and acoustic correlates of affective prosody repetition in transcortical aphasias (1996) (5)
- Apathy: who cares? (2015) (5)
- Cognitive and behavioral assessment in Parkinson’s disease (2019) (5)
- Intracortical surface‐based MR diffusivity to investigate neurologic and psychiatric disorders: a review (2021) (5)
- Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort (2020) (4)
- Triple E syndrome (2007) (4)
- The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide? (2021) (4)
- Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson’s disease (2019) (4)
- A new case of fluoxetine-induced mania in poststroke depression. (1997) (4)
- Double-blind trial of flumazenil in hemiballismus. (1994) (4)
- Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus (2022) (4)
- Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. (2021) (4)
- [Parkinson disease and cognition]. (1999) (4)
- Subcortical environmental reduplication: SPECT findings in a patient with a right thalamocapsular haemorrhage. (1993) (4)
- Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study (2022) (4)
- Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. (2002) (4)
- The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates (2020) (4)
- Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project (2021) (4)
- Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson’s Disease (2019) (4)
- Clopidogrel in secondary ischemic stroke prevention. (2008) (4)
- The Parkinson Disease Cognitive Functional Rating Scale (PD-CFRS): A Brief and Specific Instrument To Rate the Impact of PD Cognitive Symptoms on Daily Function (P06.054) (2012) (4)
- Dopaminergic mechanisms in cranial dystonia. (1988) (4)
- Language reconfiguration in bilinguals (2018) (4)
- Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. (2020) (3)
- Bilateral akinesia in drug‐induced parkinsonism after a subthalamic lesion (1994) (3)
- [Treatment of dystonic blepharospasm and hemifacial spasm with botulinum toxin: preliminary studies]. (1987) (3)
- A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene. (2019) (3)
- Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients (2022) (3)
- Chorea induced by a luteinizing hormone-releasing hormone analog (2008) (3)
- Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. (2021) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data (2022) (3)
- [Sustained attention in the preclinical phase of Alzheimer's disease]. (2003) (3)
- Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage (2021) (3)
- Structure and Dynamics of Large‐Scale Cognitive Networks in Huntington's Disease (2021) (3)
- Falls Predict Acute Hospitalization in Parkinson’s Disease (2021) (3)
- Magnetic resonance imaging pallidal hypersignal in cirrhotic subjects (1996) (3)
- Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. (2022) (3)
- SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease (2010) (3)
- Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease (2020) (2)
- Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression (2016) (2)
- Markers of reversible hepatic encephalopathy (1997) (2)
- Safinamide as Add-on Therapy – Moving Beyond Dopamine for a Multifaceted Approach in Parkinson’s Disease (2017) (2)
- Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment (2021) (2)
- Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa (2020) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Agitation and Apathy in Hyper- and Hypokinetic Movement Disorders (2003) (2)
- E30 Brain Metabolic Correlates Of Apathy And Depression In Pre-manifested Huntington’s Disease: A 18-fgd Pet Study (2014) (2)
- Associations Between Diabetic Retinopathy and Parkinson's Disease: Results From the Catalonian Primary Care Cohort Study (2022) (2)
- Mood in Parkinson's disease: From early‐ to late‐stage disease (2020) (2)
- Parkinson's Disease-Cognitive Rating Scale (2020) (2)
- Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington’s Disease (2022) (2)
- Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers (2022) (2)
- Brief cognitive tests in the screening of dementia in Parkinson's disease (2011) (2)
- Corrigendum: Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. (2020) (2)
- depression : Systematic review and meta-analysis Repetitive transcranial magnetic stimulation for the treatment of (2011) (2)
- Genotype–Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities (2022) (2)
- Advances with MRI in Parkinson disease (2012) (2)
- Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death (2018) (1)
- Parkinson’s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up (2021) (1)
- Evaluation of doctor/patient satisfaction with the use of the Parkinson's Disease Dementia-Short-Screen (PDD-SS): a screening test for dementia in Parkinson's disease (DIFFUSION study). (2011) (1)
- H15 Prevalence And Phenomenology Of Psychotic Symptoms In Huntington’s Disease (2014) (1)
- Clinical and structural brain correlates of hypomimia in early‐stage Parkinson's disease (2022) (1)
- MNCD: A New Tool for Classifying Parkinson’s Disease in Daily Clinical Practice (2021) (1)
- [Initial treatment of Parkinson's disease]. (1997) (1)
- A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease (2022) (1)
- The role of attentional control over interference in minor hallucinations in Parkinson's disease. (2022) (1)
- Cognitive and Affective Empathy in Huntington's Disease. (2021) (1)
- A collection of three integration-free iPSCs derived from old male and female healthy subjects. (2019) (1)
- C08 Set-shifting Deficits In The Pre-symptomatic Bachd Transgenic Rat Model Of Huntington’s Disease (2014) (1)
- [Fragile X tremor ataxia syndrome (FXTAS): a new kind of spinocerebelar ataxia associated to fragile X syndrome premutation carriers]. (2009) (1)
- Ballismus and mania‐RRR (1994) (1)
- Neural signatures of predictive language processing in parkinson’s disease with and without mild cognitive impairment (2020) (1)
- Parkinson's Disease Cognitive Functional Rating Scale (2019) (1)
- J01 Cognitive alterations in Huntington's disease (2012) (1)
- Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson’s disease (2022) (1)
- Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64]. (2016) (1)
- [New treatments in movement disorders]. (1999) (1)
- II.4 The role of dopamine in Parkinson's Disease-related cognitive dysfunction (2006) (1)
- Sensorimotor hallucinations in Parkinson’s disease (2020) (1)
- [Postural tremor: clinical and neurophysiological study in a consecutive series of 300 patients]. (2001) (1)
- “Prodromic” tremor: Prevalence and clinical correlates (2007) (1)
- Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene. (2019) (1)
- Is COVID-19 Expansion a Consequence of a Group Inaction? (2021) (1)
- [Paraneoplastic thrombosis of the upper longitudinal sinus, chronic disseminated intravascular coagulation and mental neuropathy in a female patient with carcinoma of the breast]. (1986) (1)
- Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 1 of the MOVES-PD study (2020) (1)
- Transcranial magnetic stimulation for treating depression (Review) (2005) (1)
- Smoking is associated with age at disease onset in Parkinson's disease. (2022) (1)
- [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease]. (1999) (1)
- Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntington's Disease. (2021) (1)
- Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson’s disease mild cognitive impairment (2021) (1)
- Non-demented Parkinson’s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes (2016) (0)
- Delineating apathy profiles in Huntington's disease with the short-Lille Apathy Rating Scale. (2022) (0)
- 1.253 HYPERHOMOCYSTEINEMIA AS A POSSIBLE CAUSE OF HEMICHOREA-HEMIBALLISMUS-SYNDROME (2012) (0)
- 1.090 HALLUCINATIONS IN DRUG-NAÍVE, NEWLY-DIAGNOSED PARKINSON'S DISEASE (2012) (0)
- Author response to Wang et al. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment? (2020) (0)
- Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study (2021) (0)
- MARKERS OF REVERSIBLE HEPATIC ENCEPHALOPATHY. AUTHORS' REPLY (1997) (0)
- MAGNETIC RESONANCE IMAGING PALLIDAL HYPERSIGNAL IN CIRRHOTIC SUBJECTS. AUTHORS' REPLY (1996) (0)
- Subject Index Vol. 51, 2004 (2004) (0)
- Oral dopamine agonists in the management of Parkinson's disease (2016) (0)
- O.104 Cognitive dysfunction/dementia (2009) (0)
- Understanding visual hallucinations: a new synthesis. (2023) (0)
- H05 Prevalence And Correlates Of Neuropsychiatric Symptoms In Pre-manifested And Early Stage Huntington’s Disease (2014) (0)
- II.P10 Cortical neuropsychological impairment differentiates Parkinson's Disease patients with and without dementia (2006) (0)
- Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up (2021) (0)
- New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
- Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data (2022) (0)
- [Premotor potential (Bereischaftspotential) in writer's cramp]. (2001) (0)
- Drug treatment and behavior (2013) (0)
- Neuropsychological Alterations in Patients (2017) (0)
- Open-Label Study of Autologous Bone-Marrow-Derived Mesenchymal Stem Cells in Multiple Sclerosis (P3.279) (2015) (0)
- Safinamide as a Valuable Add-on Therapy – Exploring New Approaches to Parkinson’s Disease Management Through Patient Case Presentations (2017) (0)
- Pseudoathetotic movements due to cervical stenosis mimicking a thalamic hand syndrome (2009) (0)
- F40 Proof-of-concept study testing SOM3355, a VMAT2 inhibitor for the treatment of chorea in huntington’s disease (2021) (0)
- A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. (2021) (0)
- パーキンソン病認識評定尺度(PD-CRS)-パーキンソン病に特有の新しい認識スケールの妥当性確認 (2006) (0)
- A differential memory profile in patients with subjective memory complaints and normal MMSE score: Depression or cognitive decline? (2000) (0)
- [Negative cortical myoclonus]. (1998) (0)
- 2.264 NEUROPSYCHIATRIC PROFILE OF PATIENTS ON TREATMENT WITH PRAMIPEXOLE, ROPINIROLE OR LEVODOPA IN MONOTHERAPY: HEAD-TO-HEAD COMPARISON (2012) (0)
- A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease (2022) (0)
- Theta/alpha band suppression and clinical outcomes during GPi‐DBS in Huntington's disease (2022) (0)
- Sphincter dysfunction in a case of cauda equina disorder: An atypical variant of autoimmune lumbosacral polyradiculoneuropathy (2013) (0)
- IV.5 The role of the dopaminergic system in dementia associated with Parkinson's Disease (2006) (0)
- ASSESSMENT OF MOTOR SYMPTOMS IN A LONG-TERM SAFETY STUDY OF RIVASTIGMINE CAPSULES AND PATCH IN PATIENTS WITH DEMENTIA ASSOCIATED WITH PARKINSON'S DISEASE (2011) (0)
- Autoscopic phenomena as an atypical psychiatric presentation of Huntington's disease: A case report including longitudinal clinical and neuroimaging data (2020) (0)
- Parkinson's Disease‐Cognitive Rating Scale (PD‐CRS): Normative Data and Mild Cognitive Impairment Assessment in Brazil (2023) (0)
- The Parkinson’s Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations (2021) (0)
- Theta oscillations and minor hallucinations in Parkinson’s disease reveal decrease in frontal lobe functions and later cognitive decline (2022) (0)
- Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information (2020) (0)
- Clinical and functional description of a new form of autosomal recessive familial parkinsons disease with late onset (2010) (0)
- A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease. (2023) (0)
- Correction to: Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease (2021) (0)
- Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease. (2023) (0)
- A11 Skin fibroblasts from huntington´s disease patients show distinct signature of MIRNAS expression along disease progression (2018) (0)
- Sudden-Onset Mutism and Parkinsonism in a Psychiatric Patient: An Unusual Case of “Central Pontine Myelinolysis” (2012) (0)
- Spectrum of disorders with dementia and parkinsonism (2015) (0)
- F24 Unsupervised clustering reveals longitudinal psychiatric signatures in HD (2021) (0)
- D10 Plasma extracellular small RNAS are early deregulated in Huntington’s disease and correlate with cognitive symptoms (2022) (0)
- Response to letter: “Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson's disease” (2022) (0)
- [Pramipexole and Parkinson's disease, an update]. (2008) (0)
- Mental and Cognitive Disturbances in Parkinson’s Disease (2006) (0)
- Predictors of clinically significant quality of life impairment in Parkinson’s disease (2021) (0)
- Monday, 9 July: Posters (2001) (0)
- D23 The effect of cognitive reserve on age of onset and executive functions in huntington’s disease and its neurobiological bases (2016) (0)
- Contents Vol. 41, 2016 (2016) (0)
- [Phenomenon of complete inversion of the visual image in an episode of transient vertebrobasilar ischemia]. (1994) (0)
- [Treatment of Parkinson's disease with COMT inhibitors: tolcapone]. (1998) (0)
- E06 Temporo-spatial structural characterization of deep white matter tracts across the spectrum of Huntington’s disease (2022) (0)
- Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson’s Disease (2019) (0)
- Structural and metabolic brain correlates of arithmetic word‐problem solving in Huntington's disease (2023) (0)
- Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson’s Disease (2023) (0)
- Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176 (2020) (0)
- PATHOLOGICAL GAMBLING IN PD : DISEASE OR DRUG RELATED ? (2010) (0)
- Changes in Principal Caregiver Mood Affects the Mood of the Parkinson’s Disease Patient: The Vicious Cycle of Illness (2023) (0)
- 2-12-15 Tacrine and extrapyramidal signs in Alzheimer's disease (1997) (0)
- Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Cognitive assessment in Parkinson’s disease (2013) (0)
- Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? (2017) (0)
- Structural brain correlates of irritability and aggression in early manifest Huntington’s disease (2020) (0)
- [Extrapyramidal effects of antipsychotic drugs]. (2003) (0)
- D20 Altered levels of brain extracellular vesicle subpopulations in Huntington’s disease (2022) (0)
- Reversible Unilateral Parkinsonism Associated With Bipolar Affective Disorder in a 59-Year-Old Spanish Woman (2012) (0)
- Spectrum of disorders with parkinsonism and dementia (2010) (0)
- Parkinson ’ s Disease Sa namide – A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems (2016) (0)
- D24 Intact emotional impulsivity in huntington’s disease despite altered structural connectivity in the uncinate fasciculus (2016) (0)
- Cerebellar syndrome induced by hypomagnesemia: A treatable cause of ataxia not to be missed. Report of three cases and a review of the literature (2023) (0)
- Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life. (2023) (0)
- Measuring the functional impact of cognitive impairment in Huntington’s disease (2022) (0)
- Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints. (2023) (0)
- Impulsivity, but not dopamine agonists, explains severity of impulse control disorders in PD (2015) (0)
- Contents Vol. 51, 2004 (2004) (0)
- [Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease]. (1998) (0)
- Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire (2018) (0)
- Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease. (2022) (0)
- [Validation of the translation to Catalan and Spanish of cognitive evoked potential N400]. (2003) (0)
- ArticlePresent and Future of Parkinson’s disease in Spain: PARKINSON- (2021) (0)
- [Paradoxal growth of cerebral tuberculomas during antituberculosis treatment]. (1997) (0)
- Posters on Display (2017) (0)
- Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders (2022) (0)
- Suicidal ideation among people with Parkinson's disease and comparison with a control group. (2023) (0)
- Parkinson's Disease-Cognitive Rating Scale--Alternative Version (2019) (0)
- P1-068 Non differential attention performance in aging and mild cognitive impairment (2004) (0)
- Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson’s disease patients and its association with cognitive decline (2019) (0)
- P102 A long-term study on the safety of rivastigmine capsule and patch in mild to moderate Parkinson’s disease dementia (2011) (0)
- [Cognitive and functional decline in the stage previous to the diagnosis of Alzheimers disease]. (2003) (0)
- Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group (2023) (0)
- Theta/Alpha Band Suppression and Clinical Outcomes During Globus Pallidus Internus Deep Brain Stimulation in Huntington's Disease (2023) (0)
- The reliability of a deep learning model in external memory clinic MRI data: A multi‐cohort study (2020) (0)
- D216H Polymorphism Within TOR1A Does Not Affect Penetrance in DRD and is Not a General Modifier in Primary Dystonia (2011) (0)
- F44 Disentangling apathy subtypes in huntington’s disease: a white matter biomarker of disease profile and progression (2018) (0)
- PND25 EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSON'S DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING (2008) (0)
- 2-30-10 Ventral midbrain tegmentum abnormalities in Tourette's syndrome (1997) (0)
- Reduplicative paramnesia as an atypical form of presentation of a Heidenhain variant of Creutzfeldt-Jakob disease: A case report. (2022) (0)
- Divergent cognitive trajectories in early-stage Huntington's disease: A three-year longitudinal study. (2023) (0)
- Lamin B1 and nuclear morphology in peripheral cells as new potential biomarkers to follow treatment response in Huntington's disease (2023) (0)
- Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability (2019) (0)
- Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset (2019) (0)
- E08 Tracking the neurodegeneration pattern of the anterior thalamic radiations in HD: a focus on brain iron, white matter integrity and metabolites (2021) (0)
- Rasagiline for the treatment of parkinsonism in Huntington's disease. (2015) (0)
- Cannabis users show increased susceptibility to false memories (2015) (0)
- [Mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and chronic hepatitis C. Sequential treatment with immunosuppressors and interferon]. (1994) (0)
- The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): Methodology and feasibility (2017) (0)
- [Neuropsychological and behavioural impairments resulting from bilateral thalamic infarct]. (2003) (0)
- F4 Neurophysiological and behavioural evidence of posterior-cortical alterations associated to specific deficits on face-pareidolia recognition in premanifest huntington’s disease (2016) (0)
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in the Japanese and the Rest of the World Parkinson’s Disease Population With a GBA Mutation: Results from Part 1 of the MOVES-PD Study (809) (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jaime J. Kulisevsky?
Jaime J. Kulisevsky is affiliated with the following schools:
